The Ledger
Tempus AI agreed to pay 1.5 billion dollars for cancer-testing company Personalis, and Wall Street punished the buyer, not the seller, sending Tempus shares down as much as 8 percent. The July 20, 2026 deal has Tempus paying 16.25 dollars a share for Personalis, a 6 percent premium to Friday’s closing price and a 28 percent premium to the 30-day volume-weighted average price, for a total enterprise value of about 1.5 billion dollars net of the stake Tempus already held under a partnership the companies built since November 2023. The acquisition folds Personalis’s NeXT Personal minimal residual disease test, used to detect cancer recurrence from trace DNA after treatment, into Tempus’s AI and data platform, in a market the companies size at 20 billion dollars. Tempus plans to pay mostly in its own stock, with up to 50 percent in cash, and expects to close in late 2026 or early 2027 pending Personalis shareholder and regulatory approval. Confidence: High on the deal terms, since they come from Tempus’s own announcement and are corroborated by both companies’ SEC filings; Medium on the total value, since some outlets report a higher gross figure before netting out Tempus’s existing stake. Sources: Tempus to Acquire Personalis, Tempus AI newsroom, Tempus AI’s Form 8-K, U.S. Securities and Exchange Commission.
InMode’s independent directors told shareholders yesterday they are still weighing two rival buyout bids, and let slip a detail that reframes the fight: this is the first time Steel Partners has offered to buy the whole company, not just a majority stake. The July 20, 2026 update from InMode’s three-member special committee said it continues to evaluate a proposal from a group including chief executive Moshe Mizrahy and investor Meir Shamir alongside a competing offer from Steel Partners Holdings to acquire 100 percent of the medical aesthetics device maker, and reaffirmed its review is independent of any single shareholder or manager. The update comes a day after the deadline passed, without a public ruling, in Steel affiliate SP Strategic Holdings’ Haifa District Court bid to block the committee’s review entirely over concerns about the CEO’s dual role as bidder and boss. Steel escalated its pressure campaign in a late June letter accusing the board of “persistent and egregious governance failures,” alleging Mizrahy cut guidance and sold shares at higher prices before later buying back in. InMode holds its annual shareholder meeting July 30, 2026, the next date this could come to a head. Confidence: High on the special committee’s statement and the court timeline, since both come from InMode’s SEC filings; Medium on Steel’s governance allegations, since they originate from an interested bidder rather than an independent finding. Source: InMode’s Form 6-K on the Special Committee’s shareholder update, U.S. Securities and Exchange Commission.
Novo Nordisk sued Eli Lilly today, accusing the maker of Zepbound and Mounjaro of a “nationwide pattern” of deceptive advertising in the weight-loss drug market both companies depend on for growth. The suit, filed July 21, 2026 in the U.S. District Court for the District of New Jersey, alleges Lilly’s ads violate the Lanham Act and state unfair-competition laws by comparing Zepbound’s results against outdated, lower-dose data for Novo’s Wegovy; one television ad that has run since late April and drawn more than 700 million impressions claims patients lose 50 pounds on Zepbound versus 33 pounds on Wegovy’s 2.4 milligram dose, while Novo says a newer trial of Wegovy’s FDA-approved 7.2 milligram dose, cleared in March 2026, shows an average 47-pound loss it calls “clinically consistent” with Zepbound. Novo is asking the court to force Lilly to pull the ads, run corrective advertising, and pay damages, and says it will seek a preliminary injunction within days if Lilly does not stand down voluntarily. “What has brought us to this moment is what we now see as a nationwide pattern, by Lilly, of deceptive advertising,” Novo general counsel John Kuckelman said. “They are intentionally confusing consumers.” Confidence: High on the filing and its core allegations, corroborated across multiple outlets with a direct company quote; Medium on the specific figures cited, since this account relies on press coverage of the complaint rather than the court docket itself. Source: Novo Nordisk sues Eli Lilly over GLP-1 drug ads it calls “deceptive,” STAT.
FRONTIER SCAN: healthcare staffing is climbing out of its post-pandemic slump just as the industry’s biggest possible merger got killed by antitrust concerns, leaving smaller deals to do the consolidating instead. The overall US healthcare staffing market is projected to return to growth in 2026, roughly 2 percent, reaching about 40.2 billion dollars after declines in 2023 and 2024, with locum tenens the fastest-growing segment at about 4 percent even as travel-nursing gross margins kept falling, from 20.6 percent in 2023 to 19.3 percent in 2024, per Staffing Industry Analysts. The growth is arriving without the sector’s largest possible tie-up: Aya Healthcare’s agreed 615 million dollar, 18.61 dollar-a-share deal for Cross Country Healthcare collapsed in December 2025 after the Federal Trade Commission raised competitive concerns about combining the two largest travel-nurse staffing and scheduling-software platforms, clearing the way for Knox Lane’s smaller, 437 million dollar buyout of Cross Country instead, which won shareholder approval July 16. Locum tenens platform Barton Associates made its own bolt-on, acquiring LocumsCollective on May 6, 2026 for undisclosed terms, expanding its workforce-matching technology. Confidence: High on the Aya termination and Knox Lane deal terms, since both are confirmed by company announcements and SEC filings; Medium on the market-size and margin figures, since Staffing Industry Analysts’ full report sits behind a paywall and these figures come from its published summary. Sources: Aya Healthcare Terminates Proposed Acquisition of Cross Country Healthcare, Business Wire, Healthcare staffing to stabilize in 2025, see modest improvement in 2026, Staffing Industry Analysts, Barton Associates Acquires LocumsCollective, Barton Associates.
THE DEAL SHEET
| Target | Acquirer/Investor | Vertical | Value | Source |
|---|---|---|---|---|
| Personalis, Inc. | Tempus AI, Inc. | Precision oncology, cancer-recurrence (MRD) testing | $16.25/share, approximately $1.5 billion enterprise value | Tempus to Acquire Personalis, Tempus AI newsroom |
| AtaiBeckley Inc. | Eli Lilly and Company | Biopharma, psychedelic-derived mental health therapeutics | $6.75/share cash upfront (~$2.8 billion) plus up to $2.50/share in contingent value rights (up to ~$3.8 billion total) | Lilly to Acquire AtaiBeckley, PR Newswire |
| Select Dental Management | Guardian Dentistry Partners (majority stake) | Dental service organizations, Northeast US | Undisclosed | Guardian Dentistry Partners acquires Select Dental Management, Becker’s Dental Review |
HCA Healthcare previewed preliminary second-quarter 2026 results July 14, revenue of about 20.23 billion dollars, and cut its full-year 2026 net income guidance to 6.3 to 6.7 billion dollars from a higher prior range, citing roughly 400 million dollars in second-quarter income pressure from treating more uninsured patients who lost exchange coverage; its full earnings call is set for July 24 (HCA Healthcare Previews Second Quarter 2026 Results, HCA Healthcare investor relations). Molina reports July 22, Community Health Systems around July 22 to 23, Universal Health Services July 27, Centene around July 28, Humana and Privia Health both around July 29 to August 6, and Cigna July 30.